Blog
Tissue Regeneration Therapeutics Inc. (TRT) and Héma-Québec enter a definitive licensing agreement for the first human clinical trial of TXP-1
Toronto, Canada, June 2nd 2014: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has …
Tissue Regeneration Therapeutics Inc. (TRT) raises $3.25 Million to accelerate the development of its Mesenchymal Cell therapeutics platform
Toronto, Canada, July 10th 2013: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has …
Umbilical Cord Cells Outperform Bone Marrow Cells in Repairing Damaged Hearts
TORONTO, Ontario (13 November, 2012) – A study published this month by researchers at the …
Tissue Regeneration Therapeutics Grants Exclusive U.S. License for PeriVascular Umbilical Cord Stem Cell Technology to PerkinElmer’s ViaCord® Cord Blood Banking Business
The agreement includes a collaborative research initiative, which supports Tissue Regeneration …
Trendsetters: Canadian Company Leads Stem Cell Industry in Research and Development
TORONTO (June 14, 2011) – In the last year, two major US cord blood companies have made human …